Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Biktarvy contains three medicines: bictegravir, emtricitabine, and tenofovir alafenamide. Two of these medicines, emtricitabine and tenofovir alafenamide, have been used to treat HIV for many years.

Biktarvy is used in adults and certain children to treat HIV-1 (the most common type of HIV.) Children receiving Biktarvy must weigh at least 14 kilograms (kg).

Biktarvy, which is used to treat HIV, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching toward a 2033 patent cliff, the drugmaker at its HIV investor event ...

According to Gilead Sciences, no patients with M184V/I who received Biktarvy had HIV RNA ≥50 copies/mL at week 48. No cases of treatment-emergent resistance were reported in the final analysis.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

The Advancing Access program covers up to $7,200 in annual copays and there’s no monthly limit for Biktarvy. In fact, 90% of program participants pay $0 for their monthly Biktarvy prescription.

Biktarvy is a 3-drug combination of bictegravir, an HIV-1 integrase strand transfer inhibitor, and emtricitabine and tenofovir alafenamide, both HIV-1 nucleoside analog reverse transcriptase ...

Biktarvy, Gilead's latest triple therapy, was approved by the FDA in February 2018 as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history ...